Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of specific cellular pharmaceutical mixture in skin beauty

A technology of drugs and mesenchymal stem cells, applied in the field of biomedicine

Inactive Publication Date: 2017-03-15
SOUTH CHINA INSTITUDE OF BIOMEDICINE
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Similarly, facial depressed scars caused by factors such as acne and trauma have also brought infinite troubles and pains to people.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of specific cellular pharmaceutical mixture in skin beauty
  • Application of specific cellular pharmaceutical mixture in skin beauty

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] In this example, the inventors screened the combination of mesenchymal stem cells from different sources with collagen or hyaluronic acid or calcium hydroxyapatite (microcrystalline porcelain) or polylactic acid or fat or platelet-rich plasma. Improve the effect of cell activity. In this embodiment, the cells to be improved are fibroblasts. Mesenchymal stem cells from different sources include: cord blood-derived, peripheral blood-derived, umbilical cord-derived, placenta-derived, Amniotic membrane-derived, bone marrow-derived, periosteum-derived, adipose-derived, tooth-derived, etc. The inventors found that compared with other sources of mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells belong to medical waste, have lower cell immunogenicity, and have certain versatility. The obtained cells are of high quality and large quantity , The purity is also higher. Furthermore, in subsequent experiments, the inventors selected a pharmaceutical composition ...

Embodiment 2

[0055] In this example, the inventors observed and identified the morphology and phenotype of the selected umbilical cord mesenchymal stem cells. The results are described below:

[0056] The morphology of umbilical cord mesenchymal stem cells showed that the cells adhered to the wall, showed spindle shape, and grew in sheets. Specific forms such as figure 1 shown. Umbilical cord mesenchymal stem cells in figure 1Under the growth state of umbilical cord mesenchymal stem cells, the proliferative ability of umbilical cord mesenchymal stem cells is strong, and the cytokines secreted including bFGF, VEGF, IGF, etc. stem cell.

[0057] The inventor identified by flow cytometry that the selected umbilical cord mesenchymal stem cells express CD90 (positive cell rate: 99%), CD105 (positive cell rate: 99%), CD73 (positive cell rate: 99%), and do not express HLA -DR, CD14, CD19, CD34 and CD45, the results are as figure 2 shown.

Embodiment 3

[0059] In this example, the inventors further sorted the obtained umbilical cord mesenchymal stem cells by cell surface markers. The inventors found that according to NG-2, Cx43, DLK1, PDGFR-α (CD140a), PDGFR-β ( CD140b), CD13, CD44, CD105, CD133, CD146, CD248, Flt-1 and KDR (CD309) at least one of the cell surface markers after sorting, the resulting mesenchymal stem cells on cell viability, vegetative cells, cell Further vascularization has a clear promoting effect.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition and application thereof; the pharmaceutical composition comprises mesenchymal stem cells and a soft tissue filler; the soft tissue filler is prepared from at least one of collagen, hyaluronic acid, calcium hydroxyapatite, polylactic acid, fat and platelet-rich plasma, wherein the mesenchymal stem cells are those sorted according to a cellular surface marker. The pharmaceutical composition is used for improving cellular activity, such as the activity of fibroblasts; compared with the prior art, the pharmaceutical composition has the advantages of low immunogenicity, high acting speed, naturalness, lasting effect, low risk, and good therapeutic effect. The pharmaceutical composition is effective for removing wrinkles, defying age, repairing scars and wounds, and the like.

Description

technical field [0001] The present invention relates to the field of biomedicine, specifically, the present invention relates to a pharmaceutical composition and its application. Background technique [0002] From ancient times to the present, beauty is an eternal topic. But as time goes by, no matter how much you maintain and love it, it cannot stop the natural sagging and wrinkling of the skin. This makes people, especially many beauty-loving ladies, show an aging look, weaken self-confidence and personal charm, produce negative emotions, and affect the quality of work and life. Equally, because the facial sunken cicatrix that factors such as acne, trauma cause also brought infinite worry and misery to people. [0003] From the perspective of skin structure, the thickness of the dermal tissue is closely related to the amount of its fibrous tissue and matrix, and is closely related to the compactness, fullness, relaxation and wrinkling of the skin. In recent years, more a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/28A61P17/00A61L27/38A61L27/24A61L27/20
CPCA61K35/28A61L27/20A61L27/24A61L27/3834A61L27/3869A61L2400/06C08L89/00C08L5/08
Inventor 裴雪涛房芳何丽娟谢小燕岳文南雪姚海雷
Owner SOUTH CHINA INSTITUDE OF BIOMEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com